The improvements could not be attributed to the mask alone
In the quiet but consequential arena of consumer protection, the UK's Advertising Standards Authority has ruled that Beauty Pie overpromised what its £199–£299 LED face mask could deliver — banning claims of clinically proven wrinkle reduction in four weeks. The ruling turns on a familiar tension in the age of at-home wellness technology: the distance between what a device might do under ideal conditions and what it demonstrably does for ordinary people using it as sold. It is a reminder that the language of science, borrowed without its rigour, is itself a kind of deception.
- A London Underground ad confidently told commuters that Beauty Pie's LED mask was 'clinically proven' to reduce wrinkles in four weeks — a claim now banned by the UK's advertising regulator.
- The trial underpinning that claim involved just 28 people, no placebo group, and additional skincare products not included with the mask — flaws the ASA found impossible to overlook.
- Because trial participants used an exfoliating product and hydrogel alongside the mask, any improvements could not be attributed to the LED device alone, collapsing the evidentiary foundation of the ad.
- Beauty Pie argued that sample sizes of 20–25 are accepted by other regulators, but the ASA held firm, demanding robust, product-specific evidence before such bold assertions can be made again.
- The mask remains on sale, but its marketing must change — and the ruling sends a wider signal to the booming at-home beauty tech industry that clinical language carries regulatory consequences.
A Beauty Pie advertisement on the London Underground has been banned after the UK's Advertising Standards Authority found the company had overstated what its LED face mask could do. The device, priced at £199 for members or £299 for non-members, was marketed as 'clinically proven to reduce wrinkles in four weeks' — a claim the watchdog determined was not adequately supported.
Beauty Pie had conducted a four-week trial with 28 participants aged 30 to 65, reporting that 92 percent felt their fine lines appeared less visible. But the ASA identified critical flaws in the study's design. There was no control group to establish whether improvements came from the LED technology itself or simply from using any skincare device. The sample size was considered too small for reliable conclusions. And crucially, participants had used an exfoliating product and a hydrogel alongside the mask — neither of which comes with the product when customers buy it — meaning the results could not be attributed to the mask alone.
The gap between how the product was tested and how customers were instructed to use it deepened the problem. Beauty Pie's own website told buyers to apply the mask to clean, dry skin, with no mention of the additional products used in the trial. Other studies the company cited as supporting evidence were also found insufficient.
LED technology is well-established in clinical medicine, used to treat conditions from acne to eczema, but the distance between professional and at-home applications remains significant. Beauty Pie argued that sample sizes of 20 to 25 are routinely accepted by other regulators, but the ASA was unmoved, ordering the company not to repeat the claim without robust, product-specific evidence. The mask stays on sale — but the promises made around it will have to be far more modest.
A London Underground advertisement for Beauty Pie's LED face mask has been pulled from circulation after the UK's Advertising Standards Authority determined the company had overstated what the device could do. The mask, which costs £199 for members or £299 for non-members, was marketed with the claim that it was "clinically proven to reduce wrinkles in four weeks." The watchdog found no adequate evidence to support this assertion.
Beauty Pie, a membership-based cosmetics company that positions itself as offering luxury formulas at accessible prices points, had conducted a trial involving 28 people aged 30 to 65 over a four-week period. The company reported that 92 percent of participants either agreed or strongly agreed that their fine lines appeared less visible after using the mask. On the surface, this seemed like solid support for the claim. But the ASA, which polices advertising standards across the UK, identified several fundamental problems with how the test was designed and executed.
The most glaring issue was the absence of a control group—no one using a placebo mask to establish whether improvements came from the LED technology itself or simply from the act of using a skincare device. The sample size of 28 people, while the company argued was consistent with standards accepted by other regulators, struck the ASA as too small to draw reliable conclusions about a product's effectiveness. There was another complication: the people in the trial had been instructed to use an exfoliating product and a hydrogel alongside the mask, neither of which are included in the package when customers buy it. This meant the results could not be attributed to the mask alone—the improvements might have come from the additional products, or from some combination of all three.
When the ASA reviewed the product listing on Beauty Pie's own website, it found instructions saying the mask should be used on clean, dry skin, with no mention of the exfoliating product or hydrogel that had been part of the trial. This gap between how the product was tested and how customers were told to use it further undermined the company's claims. The ASA also examined other studies Beauty Pie pointed to as supporting evidence and found them insufficient to substantiate the four-week wrinkle-reduction claim.
LED technology itself is well-established in medical contexts, where it has been used to treat eczema, acne, psoriasis, and sun damage. At-home LED devices have become increasingly popular in recent years, riding a wave of consumer interest in accessible skincare technology. But the gap between what LED can do in a clinical setting and what an at-home mask can accomplish remains significant—and the ASA's ruling suggests that companies marketing these devices need to be far more careful about the claims they make.
Beauty Pie argued that sample sizes of 20 to 25 people are routinely accepted by other regulators, implying that its 28-person trial should have been sufficient. The ASA was unmoved. The watchdog determined that the advertisement, which also described the mask as "skin tech that's light years ahead," required "robust, product-specific evidence" to back up such bold assertions. The company has been ordered not to repeat the claim unless it can provide evidence that meets the ASA's standards. For now, the mask remains on sale, but the marketing around it will have to change.
Citas Notables
The reported improvements in the appearance of wrinkles could not be attributed to the mask alone— Advertising Standards Authority ruling
Sample sizes of 20 to 25 are routinely accepted by other regulators— Beauty Pie's response to complaint
La Conversación del Hearth Otra perspectiva de la historia
Why does a sample of 28 people matter so much? Isn't that a reasonable number for testing a consumer product?
The size itself isn't necessarily the problem—it's what you're trying to prove. If you want to claim something is "clinically proven," you need enough people that the results couldn't just be random chance. Twenty-eight is small for that kind of claim, especially when you're making a very specific promise: wrinkles reduced in exactly four weeks.
But Beauty Pie said other regulators accept samples of 20 to 25. Why wouldn't the ASA accept that standard?
Because the ASA is looking at the totality of the evidence, not just the sample size. The real problem wasn't just that 28 is small—it's that there was no control group. No one knows if the improvements came from the mask or from the exfoliating product and hydrogel people were also using.
So the company essentially contaminated its own trial?
Not intentionally, probably. But yes—they tested the mask as part of a three-product routine, then told customers to use it alone on clean, dry skin. You can't claim the results prove the mask works when the people who got those results were using different products than what you're selling.
Is LED technology itself questionable, or just the way Beauty Pie tested it?
LED works fine in medical settings for specific conditions. The question here is whether an at-home device can do what the company claims, and whether they've actually proven it. The ASA isn't saying the mask is useless—just that Beauty Pie hasn't shown the evidence to back up the specific claim they made.
What happens now?
Beauty Pie can't run that ad anymore. They could try again with a better study—larger sample, placebo control, testing the mask exactly as customers would use it. But they'd have to start over.